2.54
2.54 (0%)
As of Feb 14, 2025
2seventy Bio, Inc. [TSVT]
Source:
Company Overview
2seventy Bio, Inc is a cell therapy company focused, together with our partner, BMS, on the commercialization and delivery of Abecma (idecabtagene vicleucel, or ide-cel), the first chimeric antigen receptor, or CAR, T cell therapy approved by the U.S. Food and Drug Administration, to multiple myeloma patients in the United States.
| Country | United States |
| Headquarters | cambridge, massachusetts |
| Phone Number | (617) 675-7270 |
| Industry | manufacturing |
| CEO | Nick Leschly |
| Website | www.2seventybio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $37.9 |
| Operating Profit | $-115.4 |
| Net Income | $-57.2 |
| Net Cash | $-3.8 |
Profit Ratios
| Gross Margin | $37.9 |
| Operating Margin | -304.9 |
| Profit as % of Revenues | -66.1% |
| Profit as % of Assets | -11% |
| Profit as % of Stockholder Equity | -27.2% |
Management Effectiveness
| Return on Equity | -27.2% |
| Return on Assets | -11.9% |
| Turnover Ratio | 7.3% |
| EBITA | $-115.4 |
Balance Sheet and Cash Flow Measures
| Total Assets | $479.5 |
| Total Liabilities | $268.7 |
| Operating Cash Flow | $-85 |
| Investing Cash Flow | $80.8 |
| Financing Cash Flow | $0.4 |
